Compare SA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SA | OPK |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 1.0B |
| IPO Year | N/A | 1995 |
| Metric | SA | OPK |
|---|---|---|
| Price | $29.50 | $1.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $65.00 | $2.28 |
| AVG Volume (30 Days) | 1.1M | ★ 3.2M |
| Earning Date | 11-12-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $642,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $1.11 |
| 52 Week High | $31.35 | $2.04 |
| Indicator | SA | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 43.99 |
| Support Level | $28.31 | $1.30 |
| Resistance Level | $30.13 | $1.42 |
| Average True Range (ATR) | 1.49 | 0.05 |
| MACD | -0.16 | -0.00 |
| Stochastic Oscillator | 48.18 | 25.16 |
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.